Tunitas is dedicated to the discovery and development of novel therapeutics designed to transform the treatment of patients with serious allergic diseases. Our proprietary platform facilitates the generation of fusion proteins that target novel inhibitory pathways on allergic cells, leading to inhibition of the key mediators of allergic hypersensitivity and the production of IgE, the antibody class that triggers the allergic response. Epsi-gam, our lead drug candidate, is designed as a long-term treatment for any IgE-mediated disease, including asthma and severe food allergy. The molecule has recently entered phase 1 clinical trials. Specific treatments for cat allergy and peanut allergy will follow epsi-gam into the clinic.